Literature DB >> 407012

Analogues of hexamethylmelamine. The anti-neoplastic activity of derivatives with enhanced water solubility.

A J Cumber, W C Ross.   

Abstract

The preparation of some water soluble analogues of the tumour growth inhibitory hexamethylmelamine is described. The ultra-violet absorption characteristics, solubility and n-octanol/water partition coefficients of these new derivatives and some related compounds have been determined. Rates of demethylation by a liver microsomal preparation and anti-tumour assays against the ADJ/PC6A mouse plasma cell tumour and a human lung tumour xenograft are reported. Two of the derivatives, pentamethylmelamine and N2, N4, N6-trimethyl-N2, N4, N6-trimethylolmelamine, which have shown activity against the xenograft are potential candidates for clinical trials using the intravenous route of administration.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 407012     DOI: 10.1016/0009-2797(77)90097-7

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  8 in total

1.  Superior efficacy of trimelamol to hexamethylmelamine in human ovarian cancer xenografts.

Authors:  E Boven; M M Nauta; H M Schlüper; C A Erkelens; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activation.

Authors:  C J Rutty; I R Judson; G Abel; P M Goddard; D R Newell; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  The comparative pharmacokinetics of pentamethylmelamine in man, rat, and mouse.

Authors:  C J Rutty; D R Newell; J R Muindi; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 4.  Clinical pharmacokinetics of altretamine.

Authors:  G Damia; M D'Incalci
Journal:  Clin Pharmacokinet       Date:  1995-06       Impact factor: 6.447

Review 5.  Hexamethylmelamine and hexamethylmelamine hydrochloride.

Authors:  H P van de Vaart-van Zutphen; C F Smulders; J Renema; A Hulshoff
Journal:  Pharm Weekbl Sci       Date:  1982-04-23

6.  British Association for Cancer Research 22nd Annual general meeting. 13-15 April 1981. Abstracts.

Authors: 
Journal:  Br J Cancer       Date:  1981-08       Impact factor: 7.640

7.  Low central nervous system penetration of N2,N4,N6,-trihydroxymethyl-N2,N4,N6,-trimethylmelamine (Trimelamol): a cytotoxic s-triazine with reduced neurotoxicity.

Authors:  I R Judson; C J Rutty; G Abel; M A Graham
Journal:  Br J Cancer       Date:  1986-05       Impact factor: 7.640

8.  Pentamethylmelamine (PMM): Phase I clinical and pharmacokinetic studies.

Authors:  J R Muindi; D R Newell; I E Smith; K R Harrap
Journal:  Br J Cancer       Date:  1983-01       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.